|Awarded On||September 14, 2022|
|Title||Identification of enhancers of T-cell anti-tumor activity in PDAC using CRISPR activation screening|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Anirban Maitra|
*Pending contract negotiation
Pancreatic cancer has one of the lowest survival rates of any cancer and in most cases does not respond to treatment. In the last decade, immunotherapy, therapy that attempts to activate the patient's own immune system to attack the tumor, has reshaped the landscape of cancer care. Effective immunotherapy relies on the immune cells (e.g. T-cells) being able to travel to the tumor, recognize the cancer cells and ultimately kill them. Despite most pancreatic cancer tumors harboring genetic mutations that would allow immune cells to recognize them, immunotherapy has so far not been effective in treating pancreatic cancer. This is believed to result from multiple factors including: (1) the stron...